GlassScriptPhysician profile
Fakhar Abbas
NPI 1578022422
$2,691.09
in general payments reported to CMS, 2019-2025
13 companies · $1,195 in 2025
The $1,195 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $689 · 2024: $691 · 2025: $1,195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,485 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,485.10 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.89 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $475.86 | 2023-2025 | Lupkynis |
| Amgen INC. | $440.48 | 2022-2025 | Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $256.57 | 2023-2024 | Saphnelo, Andexxa |
| Horizon Therapeutics Plc | $158.22 | 2023 | Tepezza, Krystexxa |
| Glaxosmithkline, LLC. | $152.03 | 2023-2025 | Benlysta |
| Sobi, INC | $124.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $122.53 | 2025 | |
| Ucb, INC. | $106.01 | 2023-2025 | Cimzia, Bimzelx |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Radius Health, INC. | $32.27 | 2025 | Tymlos |
| Ani Pharmaceuticals, INC. | $29.20 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $14.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fakhar Abbas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.